Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Y-mAbs Therapeutics Inc YMAB

Healthcare Biotechnology
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product... see more

Recent & Breaking News (NDAQ:YMAB)

Y-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial Guidance

GlobeNewswire May 8, 2023

Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023

GlobeNewswire April 28, 2023

Y-mAbs Announces Presentation of Naxitamab data at AACR

GlobeNewswire April 18, 2023

Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA

GlobeNewswire April 5, 2023

Y-mAbs Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments

GlobeNewswire March 30, 2023

Y-mAbs to Announce 2022 Financial and Operating Results on March 30, 2023

GlobeNewswire March 21, 2023

FINAL DEADLINE ALERT: Scott+Scott Attorneys at Law LLP Reminds Investors That a Securities Class Action Has Been Filed Against Y-mAbs Therapeutics, Inc. (YMAB) Lead Plaintiff Deadline is March 20, 2023

Newsfile March 20, 2023

DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 20, 2023 in Y-mAbs Lawsuit - YMAB

Newsfile March 20, 2023

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Y-mAbs Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile March 20, 2023

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Y-mAbs Investors of a Lead Plaintiff Deadline of March 20, 2023

PR Newswire March 20, 2023

YMAB FINAL DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact Firm's Attorneys Before Mar. 20th Deadline in Securities Fraud Class Action

Newsfile March 19, 2023

1 DAY UNTIL DEADLINE: Scott+Scott Attorneys at Law LLP Reminds Investors That a Securities Class Action Has Been Filed Against Y-mAbs Therapeutics, Inc. (YMAB) Lead Plaintiff Deadline is March 20, 2023

Newsfile March 19, 2023

Y-mAbs Shareholder Notice

Newsfile March 19, 2023

Y-MABS INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Y-mAbs To Contact Him Directly To Discuss Their Options

PR Newswire March 18, 2023

Y-MABS THERAPEUTICS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. - YMAB

Business Wire March 17, 2023

Y-mAbs Shareholder Notice

Newsfile March 17, 2023

Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Y-mAbs Therapeutics, Inc. (YMAB) Investors and Encourages Investors to Contact the Firm Before March 20, 2023

Newsfile March 17, 2023

Y-mAbs Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 20, 2023 to Discuss Your Rights - YMAB

Newsfile March 17, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Y-mAbs Therapeutics, Inc. - YMAB

Newsfile March 17, 2023

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (YMAB)

Business Wire March 17, 2023